Waters Corporation Beats Q1 2026 Revenue Expectations, Raises Full-Year Guidance
Event summary
- Waters Corporation reported Q1 2026 revenue of $1.267 billion, exceeding guidance by $56 million.
- Organic revenue grew 13% as reported and 11% in constant currency, driven by strong performance in Analytical Sciences Division.
- Biosciences and Diagnostic Solutions businesses generated $520 million in revenue, $40 million above guidance.
- Adjusted EPS grew 20% year-over-year to $2.70.
- Company raised full-year 2026 organic constant currency revenue growth guidance to 6.5% to 8.0%.
The big picture
Waters Corporation's strong Q1 2026 performance highlights the successful integration of its recent acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions businesses. The company's ability to exceed revenue expectations and raise full-year guidance reflects its strategic focus on combining analytical technologies with advanced diagnostics. This positions Waters to capitalize on growing demand for high-volume testing environments in life sciences, particularly in areas like disease detection and antibiotic resistance management.
What we're watching
- Integration Execution
- How Waters will sustain the strong start of its Biosciences and Advanced Diagnostics Divisions post-acquisition.
- Revenue Synergies
- Whether the company can achieve the expected $15 million in revenue synergies for the full year.
- Market Dynamics
- The pace at which the instrument replacement cycle and new product launches will continue to drive organic revenue growth.
Related topics